← BackACCURAY INC · Surgical & Medical Instruments & ApparatusARAY
High riskNext report: Due any day
The short versionA company still losing money with shrinking sales, with elevated risk. Institutions are trimming.
Watch out for
- Sales down 21% in the latest quarter vs a year ago
- Losing money
- High debt: 2.54x equity
Money moves
- No insider buying or selling in the last 30 days
- Institutions cut 5.4% from their holdings in the quarter ending June 2026 (61 bought, 67 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$0.12-7.7% that day
From ARAY's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26 (worked out from yearly totals)$100.9M-21% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $401.9M, down 12% from the 12 months before. Over 5 years, sales grew about 3.7% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.-3.1%
- MissDebt under half of equityNot relying on borrowed money.2.54x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-0.3%
- MissProfitable every yearSteady profits, not one good year.1 of 10 years
- MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$1.4M
- MissShare count not growingNot diluting owners. Falling means buybacks.+11.6% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.32.1%
- Revenue
- $458.5M
- +2.7% vs prior year
- 5-year growth
- +3.7%/yr
- revenue, per year
- Total debt
- $135.9M
- 2.54x equity
- Current ratio
- 1.47x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $100.9M
- -20.9% YoY
- EPS
- -$0.01
- vs $0.01
- Op. margin
- 5.5%
- +2.2 pts
- Gross margin
- 34.8%
- +4.2 pts
- Free cash flow
- $2.0M
- Share count
- +6.0%
- vs a year ago
Some values are worked out from year-to-date totals in the annual report.
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.8
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▼Distributing-5.4%Institutions cut 5.4% from their holdings. 61 bought, 67 sold. 2 quarters of net selling in a row.
Shares held by institutions71.6M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+7.4%Cash runwayAt last year's cash burn
70 monthsDebt to equityLatest balance sheet: debt compared with what owners have
3.5x · $147.9M debtShares outstandingLatest reported
119MWhy high risk- Losing money
- Share count growing 7.4% a year
- High debt: 3.55x equity
- Revenue down 12.3% from the year before
- 5 offering filings in 6 months (may sell new shares)
- Exchange listing notice (a delisting warning or a move to another exchange)
- Past financials no longer reliable
- Late quarterly report notice
Next reportDue any dayEstimated from the same quarter last year
- Results filedAug 19
- Results filedMay 6
- Results filedFeb 4
- Results filedNov 5, 2025
- Results filedOct 20, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.